Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod

被引：0
|
作者：
Zhang, Peijin [1 ]
Hosein, Fareeda [1 ]
Yu, Kyungha [1 ]
Walker, Susan [1 ]
Syto, Mary [1 ]
Tirucherai, Giridhar [1 ]
Murthy, Bindu [1 ]
Tatosian, Daniel [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1107
引用
收藏
页码：S843 / S843
页数：1
相关论文
共 50 条
  • [1] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 976 - 976
  • [2] EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON QUIZARTINIB PHARMACOKINETICS
    Zahir, H.
    Lasseter, K.
    Marbury, T.
    Rondon, J.
    Bermudez, Y.
    Gammon, G.
    Kamel, Y. Mostafa
    Said, N.
    Hsu, C.
    Abutarif, M.
    Zheng, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S20 - S20
  • [3] Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
    Kletzl, Heidemarie
    Ajmi, Hassan
    Antys, Izabela
    Heinig, Katja
    Jaber, Birgit
    Marbury, Thomas C.
    Young, Annie
    Gunther, Andreas
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3749 - 3759
  • [4] THE EFFECT OF MILD TO MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF ALISPORIVIR (ALV)
    Kovacs, S. J.
    Ke, J.
    Praestgaard, J.
    Barve, A.
    Zhang, J.
    Maietta, R.
    Sunkara, G.
    Stein, D. S.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S345 - S345
  • [5] Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate
    Moore, Kenneth
    Zannikos, Peter
    Solanki, Bhavna
    Greenspan, Andrew
    Verhaeghe, Tom
    Brashear, H. Robert
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 738 - 746
  • [6] Lack of effect of mild or moderate hepatic impairment on the pharmacokinetics of rimonabant.
    Grandison, Monica K.
    Kanamaluru, Vanaja
    Bishai, Raafat
    Lockwood, Graham
    Newton, John
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1199 - 1199
  • [7] Effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat
    Khosravan, R
    Grabowski, B
    Mayer, M
    Wu, JT
    Joseph-Ridge, N
    Vernillet, L
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1083 - 1083
  • [8] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    Schnell, David
    Buschke, Susanne
    Fuchs, Holger
    Gansser, Dietmar
    Goeldner, Rainer-Georg
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Wind, Sven
    Petersen-Sylla, Marc
    Halabi, Atef
    Koenen, Ruediger
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 267 - 275
  • [9] Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
    Tortorici, Michael A.
    Toh, Melvin
    Rahavendran, S. V.
    LaBadie, Robert R.
    Alvey, Christine W.
    Marbury, Thomas
    Fuentes, Ernesto
    Green, Matthew
    Ni, Grace
    Hee, Brian
    Pithavala, Yazdi K.
    [J]. INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) : 1370 - 1380
  • [10] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    David Schnell
    Susanne Buschke
    Holger Fuchs
    Dietmar Gansser
    Rainer-Georg Goeldner
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Sven Wind
    Marc Petersen-Sylla
    Atef Halabi
    Rüdiger Koenen
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 267 - 275
12345